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In this video Q&A, we talk to Iain Frame and Sarah Cant from Prostate Cancer UK about the current
challenges in prostate cancer research and policy and how these are being addressed.
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1. What are the current challenges in prostate cancer
research and policy, and why is it important to address
them?
Iain Frame (IF): I think that there are three current chal-
lenges in prostate cancer research. The first is risk as-
sessment – assessing a man’s risk of developing prostate
cancer during his lifetime. The second is differential
diagnosis and prognosis of aggressive versus non-
aggressive cancer. The third is developing new treat-
ments for advanced disease, but also working out how
best to use existing treatments for optimal effect. These
three areas are important because they are the three key
areas that affect the outcome of a man’s diagnosis of
having prostate cancer.
Sarah Cant (SC): I think there are quite a few chal-
lenges across prostate cancer, both for men with the
disease and for the clinicians who are treating them. If
we go from the start of the patient journey, the first
issue is whether a man should have a test for prostate
cancer. As I’m sure most people know, the prostate-
specific antigen (PSA) test is not very accurate; it in-
dicates that there is a problem with the prostate, it
does not determine whether cancer is present. PSA testing
leads to a number of other diagnostic techniques that cansay whether a man has cancer, but not necessarily how ag-
gressive it will be, and may lead to a lot of men having
treatment that they may not have needed, for a cancer that
may not have harmed them.
So men are faced with the decision of whether or not
to have an inaccurate test in the first place. In fact, a lot
of men don’t even know that they may be at risk for
prostate cancer. There is quite low awareness of the
disease amongst certain groups. For example, men from
a black Afro-Caribbean ethnicity or with a family history
of the disease may be at high risk. That is the first step:
understanding whether or not a man is at high risk of
the disease, whether or not he should have the test, and
then what the implications are of being diagnosed with
prostate cancer.
Then there are questions such as, should prostate
cancer be treated? What treatment should a man have;
what should he choose? What are the side effects? What
are the impacts of particular treatments?
The next question is whether that treatment – and the
support for any associated side effects – is actually avail-
able to a particular patient where he lives.2. If we take a patient-centric view, what are the challenges
men face at the moment when they deal with prostate
cancer from diagnosis to treatment, and how can that
situation be improved?
IF: The patient’s view informs everything that we do here
at Prostate Cancer UK in terms of research. We have pa-
tients involved in research decision-making processes, so
we hear from men about what’s important to them. The
idea of a simple and effective risk assessment tool is
something that’s high on the list. Another priority is be-
ing able to tell at the point of diagnosis whether a par-
ticular cancer is likely to be aggressive and kill you, or
whether it will never leave the prostate and you will die
of something else, but with prostate cancer.
Finally, a lot of new drugs are extending the end of
life, and we need some drugs – either existing or new
agents – that have a curative effect, rather than an end
of life effect.
SC: It is important to start with a better understanding
of who is at risk from prostate cancer; for individuals
and their primary care physicians (GPs) to understand
whether or not they’re at higher than average risk, and
to be able to then make an informed decision of
whether prostate cancer tests like PSA testing are right
for them. Risk assessment needs to be a combination
of awareness – so that men are aware of the risk fac-
tors for prostate cancer and what they should be doing
about them, whether they should be acting on that –
and also for GPs to understand that, when a man is in
front of them, he may have risk factors such as his
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risk of prostate cancer, and to start a conversation
about whether or not a PSA test is the right thing.
A risk tool that would better stratify men into those
who may need a test and those who are unlikely to be
impacted by aggressive prostate cancer would help both
men and their GPs with that conversation. As you go
further through the pathway, better diagnostics – a bet-
ter understanding of a whether a man has prostate can-
cer or not, what type of prostate cancer it is – would be
helpful in understanding whether it needs treatment and
then what the most effective treatment is. Finally, when
a man has been given a choice of treatments that he is
able to access, he should have the full support for all of
the side effects that he needs. All of these things are part
of one big picture and they can all be solved. Even with-
out any further advances we think that men would have
a better deal and better outcomes than they do now if
they all received the best available standard of care, not-
withstanding any new research that might make treat-
ment or diagnosis even better.
3. What are your current research and policy
priorities?
SC: At the moment, we have based our policy priorities
around those three stages of the prostate cancer journey:
the diagnosis, treatment, and support for side effects.
Currently, a key policy priority is to improve the diagno-
sis process that we have at the moment. We know that
the PSA test is not ideal, but we also know that the
guidelines that exist to help GPs and men decide
whether PSA testing is right for them are not being
followed consistently, they’re not understood, and we
believe that something quite simple could be done to en-
sure that at least everyone is on the same page with what
we have now. We are currently working on getting a
consensus across the medial professions in the UK as to
best practice for PSA testing as it stands. The consensus
will address whether GPs should initiate conversations,
who they should be talking to, and whether men should
be offered repeat testing – these questions are not all ne-
cessarily going to be answered by years of randomized
controlled trials. At the moment, there is a lot of incon-
sistency in what GPs are saying and doing and we need
to improve this.
We feel that a small step would just be to get that
consistency and that consensus agreed across the UK;
for all men to understand their rights to a test if they
want one, to be given the right information, and to be
managed appropriately by a GP if they do ask for a test.
That is the first stage.
The second stage is looking at the availability of treat-
ment across the UK. For example, we know that access
to drugs for men with advanced prostate cancer is verydifferent depending on which country they live in. We
also know that in parts of the UK, some treatments just
aren’t available, such as high dose rate brachytherapy or
robotic surgery. We are looking at how we can improve
the situation for those men.
In particular, we are working with a coalition of char-
ities within England to work with NHS England, the
Department of Health, and pharmaceutical companies,
as well as NICE, to see if we can improve the cancer
drug commissioning process, we hope to ultimately get
affordable, effective drugs to men who need them more
quickly.
In terms of supportive side effects, from a policy per-
spective, we are looking at support for erectile dysfunc-
tion. We know that many men who have treatment for
prostate cancer will experience erectile dysfunction as a
result of it. Their results in terms of sexual function can
be improved with early treatment and also the right
treatment, but the clinical practice guidelines are out of
date. We are working to try to update those treatment
guidelines in England. We’ve got guidelines that we have
developed with clinical experts that we would like to
have adopted. We are also working in coalition with
other organisations who are interested in erectile dys-
function services for other disease areas, to see if we
have shared areas of improvement that we can work
together to achieve.
IF: Prostate Cancer UK at the moment is following a
research strategy that has three main priorities. One is
to develop a risk assessment tool. The second is to be
able to differentially diagnose aggressive versus non-
aggressive prostate cancer. The third is developing new
treatments for advanced disease.
No strategy stands still, so we are looking at the
main aims of the strategy, and to the three priorities
above I would add prevention. This does not mean
long-term expensive trials or dietary supplements; I
think we want to be able to take advantage of some of
the research that’s coming out where obesity is being
identified as a possible risk marker for prostate cancer.
We may be able to collaborate with those working in
type II diabetes or cardiovascular disease, to have
better effect and help – not just in primary prevention,
but actually to help – the secondary outcomes for
prostate cancer.
Additionally, I think that we need to be looking at
repurposing of existing drugs. We have seen some
evidence coming through where drugs that have been
used for different cancers could be potentially beneficial
in prostate cancer. Repurposing drugs helps drugs to
reach the market more cheaply; they have less of the
rigorous trials to go through because they have already
undergone a lot of safety testing. Our key priorities are the
ones that would have the most benefit to the most men.
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you give a brief outline of some new tools under
development?
IF: There are a number of risk assessment tools effect-
ively on the market that have been developed and vali-
dated. The problem is that they are not really in routine
use. We looked at what was out there, and who was
developing them, and we decided to develop a risk as-
sessment tool that was suitable to be delivered through
primary care, that was going to be reliable, relatively
cheap, and suitable for a multi-ethnic population. So we
brought together the experts that had developed those
other tools.
I think that the problem is that no matter how compli-
cated the maths or the science behind a risk assessment
tool is, it has got to be very easy to use and interpret.
We are working with a core group of scientists to help
us develop that. The important thing is that there
are a number of tools out there that we think would
be useful – and we’re following the development of
those – but actually what we want is something that
is suitable and relatively easy to use.
We see risk assessment as a key priority because it will
take some men out of the system who do not need to be
tested further or on a regular basis. There will be others
who are fired into the system and they have the best
treatments available. Then there will be those that do
not fall into these categories, so we have been looking at
what happens to those men. It should not be a perpetual
loop of coming back and getting re-tested with the same
old test. It is important to establish what additional tests
might be needed to help make the decision of whether
you become a red – and have to go and see the urologist
or oncologist; or green – and you can go away and not
come back for several years. So this is where we are at.
It’s a case of honing down and getting something that is
actually of practical value.
5. Is there a need for better diagnostic tools in prostate
cancer?
SC: There absolutely is a need for better diagnostic tools.
For a start, being diagnosed with ‘a problem with your
prostate’, as the PSA test does and the digital rectal
examination does, can lead men on a journey that in-
volves treatment and associated side-effects that they
may not need. For some men, detection may not be early
enough or treatment effective enough if they have
already got advanced disease or go on to develop ad-
vanced disease.
We really need to ensure that diagnosis is effective
and will lead to men getting the best management for
themselves and their disease. Be that, perhaps, active
surveillance if they’re considered to be at low risk of
developing an aggressive prostate cancer, or moreconservative treatment at the right time, and the most
effective treatment for that man’s particular cancer.
Diagnosis needs to be improved in two ways. There
needs to be a better way of diagnosing that a man actu-
ally has a prostate cancer, in an easy way, but also that,
prognostically, clinicians can understand whether or not
that disease is going to harm that man in his lifetime,
and how best to treat it. It is a very key role in the whole
prostate cancer journey.
One of the biggest issues is whether screening can be
developed. Is there a tool or a test that can be developed
in the future that would allow screening for men? That
is a big policy question, and it is a big policy challenge.
We know that the PSA test is not effective for screening
at a population level, but we believe there must be
something out there in the future that could help men
understand their risk of developing the disease, whether
they go on to have further tests, and whether there is a
way of diagnosing and detecting aggressive cancers at an
early stage, so that we can reduce the number of deaths
from prostate cancer.
IF: We urgently need new diagnostic and prognostic
tests. I would take it beyond just diagnosis. In prognosis,
we are looking to be able to detect, as early as possible,
whether a cancer is likely to be aggressive or not. This
would allow you to treat the cancer appropriately, and
make sure that men know how it will be treated.
It is also important to monitor treatment. We need to
be able to follow whether a treatment is working effect-
ively or not. At the moment, it is purely based on PSA.
We need to look at other biological markers or genetic
markers that will determine whether or not a man is
responding to treatment, and if not, then get him off
that treatment and onto another treatment sooner. I
think, ultimately, what I would like to see is the diagnos-
tic and prognostic tests fitting in with the risk assess-
ment, so they can be done at the same time. Yes, you’re
at risk of prostate cancer – or, yes you do have prostate
cancer – it is aggressive, and it will respond to this treat-
ment. If we can obtain more knowledge as a package, it
will help develop better treatments and we will be able
to offer a man a better deal with greater availability of
different treatment choices.
6. What are the current gaps in care for men with
prostate cancer, and what work is currently underway
to address these?
SC: There are quite a few gaps in care. For any man with
a question about prostate cancer who goes to his GP, it
is a bit of a lottery as to whether he will get the informa-
tion that he should about the risks, about PSA testing
and its pros and cons. We know that some GPs feel that
they do not have enough information to be able to pro-
vide that to a man and support him in that decision.
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testing, which may influence their patient – in this case,
the patient’s choice would not necessarily be the same as
if he was given balanced information and supported to
make a decision. Ensuring that the right information
reaches GPs and patients is a challenge, as is being
able to raise awareness of prostate cancer and the com-
plexities at that pre-diagnosis stage.
The other big gaps are in access to treatment. When a
man is diagnosed, he does not necessarily get the treat-
ment that is most appropriate for him. This can be be-
cause the first clinician he speaks to does not necessarily
give him the full range of options that he could choose,
or could be because the clinician may want to prescribe
a certain treatment that is not available. Depending on
where you live in the UK, you may or may not be able
to access certain cancer drugs. Also, things like robotic
surgery or high-dose brachytherapy are not available as
standard across the country, and these treatments will
be important for certain individuals.
The final gap in care is in terms of support. At the
moment, treatments do come with side effects. Many of
those are unavoidable, but men can be supported –
sometimes from before the treatment starts – to reduce
the impact of that side effect, be that incontinence or
erectile dysfunction, be that the psychological impact of
prostate cancer, fatigue, or bowel incontinence. We are
told by the health providers that these support services
exist, but men are saying that they are not being di-
rected towards them or they are not getting appropriate
help at an early enough stage – or any help in some
cases. This is a key gap that is easy to close; it is about
joining up men with services. In fact, we hope we
would ideally save money because if caught early
enough then these men might not develop more serious
side effects, or impacts of side effects, that need more
prolonged treatment.
7. Are there any other issues in prostate cancer research
and policy that need to be addressed?
IF: I think, no matter how good the science is, we need
to make sure there is a cadre of people being able to
carry out that science. It is not just in prostate cancer –
it’s across medical research in general – we are told that
when current clinical researchers retire, there is no one
coming through to take their place. We have to make
sure that we’re embedding people; not only training
them in prostate cancer research, but making sure that
the good ones stay in prostate cancer research. Re-
searchers will, quite rightly, move around depending on
where the high science is taking place, but we want to
bring them into prostate cancer research and keep them
there and make sure that they can help deliver on all this
great new research that is coming forward.One thing I would highlight is that we are identifying
areas where there is a need to train different disciplines
and bring them into prostate cancer. One is pathology –
academically trained pathologists – but the other is gen-
etic analysis. A lot of emerging genetic analysis work is
reliant on trained mathematicians or statisticians to take
part. So we are looking to get these specialists interested
in prostate cancer research, and they will be the ones
who are analysing these complex data and helping us
move forward.
The third thing I would add to that is that we have to
make sure that when these great research results come
forward, we translate them into patient benefit as soon
as possible. We all read scientific papers or press re-
ports on new genes being found for this, that, and the
next thing, or new biological markers; it is our role to
make sure that the results of such research are then
translated into clinical practice as quickly and efficiently
as possible.
SC: When we look forward, there are some concerns
particularly about the workforce. At the moment, we
know that the majority of men with prostate cancer get
access to a named nurse specialist. Following some
research that we have carried out, we have concerns that
there are not enough new nurses to make up for the
gaps in the number of nurses we believe will be retiring
in the next 10 years. It will be key for health providers in
the future to ensure that they have enough specialised
nurses, and that those nurses are trained and able to
support men.
8. What is your future outlook on these issues?
IF: I am hugely optimistic. I think the time is right for us
now in research. I think there are some great things
coming through and it is for us to capitalise on, and to
bring others with us. We will never be able to do this on
our own, and this is about other charities, other funders
of research joining us, and us being able to identify what
the questions are – maybe even how to go about finding
the answers to them – and then bringing us all together
to make sure that it happens. For us, it is about making
sure that whatever great research is going on, it reaches
the patient as quickly as possible.
SC: At Prostate Cancer UK, we are developing a new
strategy as we speak and we hope to publish it later this
year. The strategy will be looking to make prostate
cancer a disease that men can live with rather than die
from, and to reduce the impact of the disease on men
and their families over the next 10 years.
From a policy perspective, there are some key areas
for future development. We do need to really invest in
research and advances in diagnosis and treatment and
prevention, but we also need to use those advances –
the advances that are coming through now – and
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we could ensure that every man across the country has
the best available care today, we would already see im-
provements in outcomes. If we can build on that by en-
suring that new advances and cost-effective new
treatments are able to reach men quickly, then we would
see even better outcomes for men. I think this is where
we need to be focussing in the future.
9. What is your view on the importance of open access
publishing for prostate cancer research?
SC: I think open access publishing is important across
all of prostate cancer. Obviously, it is vital for re-
searchers who would like to understand what’s going on
in the field and to be able to share and learn from their
colleagues and peers. However, it is not just people who
are researching in the labs who need that information.
Charities such as Prostate Cancer UK pride ourselves on
our expertise and we have people with research back-
grounds who look at the published research and learn
from it to inform what we would like to see for men
with prostate cancer.
So open access publishing benefits more than just
researchers. Clinicians, charities, advocates for men with
prostate cancer, all need to see what the latest findings
are, what works, what we can learn from each other, and
together ensure that we are using that to improve things
for men.
IF: I think open access publishing is hugely important,
not just for prostate cancer research, but for all research.
We have to learn from other disciplines; we have to be
able to teach other disciplines or give them information
that’s coming through. To get that into the public do-
main as quickly and easily as possible is absolutely para-
mount. There is no point in people holding on to
information that might help others, so I think that open
access publishing is hugely important. We have it writ-
ten into our terms and conditions that researchers that
we fund investigate open access publishing and try to
publish open access as much as possible.
10. Where can I find out more?
See reference list [1–3].
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